 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- IDG16177 / Evotec, Ildong
In Vitro DILI Risk Assessment of IDG16177, a Potent and Selective GPR40 Agonist, for the Treatment of Type 2 Diabetes (Poster Hall (Halls D-E); Board No. 112) - May 11, 2022 - Abstract #ADA2022ADA_1885;
Fasiglifam induced a significant accumulation of GCA at 4 µM lower than the human Cmax of 10 µM, whereas IDG16177 showed no significant accumulation at 1 µM higher than the predicted human Cmax of 0.3 µM.IDG16177 did not have a significant effect in quantitative evaluation of the activity of various transcription factors, whereas treatment with 10 uM fasiglifam for 24 hours significantly increased the activities of peroxisome proliferator activating receptor (PPAR), activator protein 1 (AP-1) and nuclear respiratory factor 2 (NRF2), which were highly correlated with liver disease pathogenesis/progression. Interestingly, treatment with 10 μM IDG16177 for 48 h increased the activity of FXR, a master regulator of BA metabolism that inhibits BA absorption system and BA synthesis and promotes BA enterohepatic circulation, by 1.58-fold.These results show that IDG16177 has the advantage of having a low DILI potential compared to fasiglifam in addition to its potent efficacy for the treatment of type 2 diabetes.
- ||| IDG16177 / Evotec, Ildong
New P1 trial: IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics (clinicaltrials.gov) - Jul 28, 2021
P1, N=94, Recruiting, Sponsor: IlDong Pharmaceutical Co Ltd
- IDG16177 / Evotec, Ildong
[VIRTUAL] Development of IDG-16177, a Selective and Safe GPR40 Agonist for the Treatment of Type 2 Diabetes () - May 29, 2021 - Abstract #ADA2021ADA_1727;
And no phototoxicity was observed in in vitro 3T3 NRU study. These results shows that the potential for IDG-16177, a safe and effective GPR40 agonist, to treat patients with type 2 diabetes.
- IDG16177 / Evotec, Ildong
[VIRTUAL] IDG-16177, a Potent, Orally-Bioavailable GPR40 Agonist, Improves Glycemic Control and Glucose-Stimulated Insulin Secretion in Preclinical Studies () - May 29, 2021 - Abstract #ADA2021ADA_1726;
IDG-16177 1 mg/kg showed similar effective in insulin secretion fasiglifam 10 mg/kg. These results show that IDG-16177 might be an effective drug candidate for treatment of type 2 diabetes.
- IDG16177 / Evotec, Ildong
[VIRTUAL] In Vitro Pharmacodynamic Studies of IDG-16177, a Potent GPR40 Agonist, for the Treatment of Type 2 Diabetes () - May 29, 2021 - Abstract #ADA2021ADA_1725;
Although IDG-16177 shows no signal at the cAMP pathway like fasiglifam, IDG-16177 (0.1∼3 μM)-treated group enhances more insulin secretion than fasiglifam (1∼10 μM) in HIT-T15 β cells. These studies support the potential utility of IDG-16177 for the treatment of type 2 diabetes.